Abelzeta announces clinical data showing preliminary anti-tumor activity for c-car031, an armored autologous gpc3 car-t, in patients with advanced hepatocellular carcinoma, at asco annual meeting 2024

Car031 study at 9.03-mo median follow up achieves disease control rate (dcr) of 91.3% and objective response rate (orr) of 56.5% for patients across all dose levels (dls) and orr of 75.0% at dl4 rockville, md. , june 4, 2024 /prnewswire/ -- abelzeta pharma, inc. ("abelzeta" or the "company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (iit) of c-car031 in connection with the company's oral presentation at the 2024 american society of clinical oncology (asco) annual meeting.
CAR Ratings Summary
CAR Quant Ranking